Results 41 to 50 of about 157,921 (286)

A systematic review on the association between ovarian and prostate cancer with BRCA1 and BRCA2 gene

Сибирский онкологический журнал, 2023
Background. BRCA1 and BRCA2 were discussed as the basis of inherited adenocarcinoma and breast and ovarian malignancy. Ovarian cancer is uncommon in women below 40 years of age, and prostate cancer mainly occurs in older men cause 90 % in those above ...
Sarpparajan Chitra Veena, Mohammed Vajagathali, Veerabathiran Ramakrishnan   +2 more
doaj   +1 more source

DNA methylation profiling to assess pathogenicity of BRCA1 unclassified variants in breast cancer [PDF]

, 2015
Germline pathogenic mutations in BRCA1 increase risk of developing breast cancer. Screening for mutations in BRCA1 frequently identifies sequence variants of unknown pathogenicity and recent work has aimed to develop methods for determining pathogenicity.
AFFECT, Brown, R, El-Bahrawy, M, Flanagan, JM, Flower, KJ, Goldgar, DE, KConFab, Morris, JR, Parsons, MT, Shenker, NS, Spurdle, AB   +10 more
core   +1 more source

ОСОБЕННОСТИ ЭКСПРЕССИИ РЕЦЕПТОРОВ ЭСТРОГЕНОВ, ПРОГЕСТЕРОНА И АНДРОГЕНОВ ПРИ НАСЛЕДСТВЕННЫХ И СПОРАДИЧЕСКИХ ОВАРИАЛЬНЫХ КАРЦИНОМАХ

Žurnal Grodnenskogo Gosudarstvennogo Medicinskogo Universiteta, 2022
Введение. Овариальные карциномы – сложное гетерогенное заболевание с разнообразием клинико-морфологических форм. В большинстве случаев опухоли яичников экспрессируют эстрогеновые (РЭ), прогестероновые (РП) или андрогеновые (РА) рецепторы, но, в отличие ...
А. L. Savаnevich, A. V. Shulha, A. V. Kapytski   +2 more
doaj   +1 more source

RE: Universal tumor DNA BRCA1/2 testing of ovarian cancer: prescreening PARPi treatment and genetic predisposition [PDF]

, 2019
BRCA1/2 mutations play a predictive role in ovarian cancer risk evaluation. Moreover , patients are today being tested for BRCA1/2 mutations to select a tailored therapy too , because they could benefit from a treatment with PARP inhibitors (PARPi ...
Panici, Pierluigi Benedetti, Tomao, Federica, Tomao, Silverio   +2 more
core   +1 more source

Integrated genomic and proteomic profiling reveals insights into chemoradiation resistance in cervical cancer

Molecular Oncology, EarlyView.
A comprehensive genomic and proteomic analysis of cervical cancer revealed STK11 and STX3 as a potential biomarkers of chemoradiation resistance. Our study demonstrated EGFR as a therapeutic target, paving the way for precision strategies to overcome treatment failure and the DNA repair pathway as a critical mechanism of resistance.
Janani Sambath, Irene A. George, Srikanth S. Manda, Prasanth Ariyannur, Ekta R. Dhawale, Raja Sekhar Kommu, Rajan Datar, Darshana Patil, Vinita Trivedi, Manisha Singh, Kumar Prabhash, Sewanti Limaye, Richa Chauhan, Prashant Kumar   +13 more
wiley   +1 more source

BRCA1/2 associated cancer susceptibility: a clinical overview

Forum of Clinical Oncology, 2016
The most frequently identified genetic cause of breast cancer is the germline mutation of BRCA1 and 2 genes. The carriers of these mutations are at high risk for breast and ovarian cancers and increased risk for pancreatic and prostate cancers.
Lypas Georgios
doaj   +1 more source

Developing a community-based breast cancer risk prediction tool for resource-poor settings

Journal of Education and Health Promotion, 2019
BACKGROUND: With an estimation of every two women newly diagnosed with breast cancer, one dies. It is accounted that 1 in 28 women is likely to develop breast cancer during her lifetime.
Divya Pillai, Shaikh Shah Hossain, Vijay Kumar Chattu   +2 more
doaj   +1 more source

Complex-based analysis of dysregulated cellular processes in cancer [PDF]

, 2014
Background: Differential expression analysis of (individual) genes is often used to study their roles in diseases. However, diseases such as cancer are a result of the combined effect of multiple genes.
Khanna, Kum Kum, Liu, Chao, Madhamshettiwar, Piyush B., Ragan, Mark A., Simpson, Peter T., Song, Sarah, Srihari, Sriganesh   +6 more
core   +1 more source

Tumor and germline testing with next generation sequencing in epithelial ovarian cancer: a prospective paired comparison using an 18‐gene panel

Molecular Oncology, EarlyView.
Genetic testing in epithelial ovarian cancer includes both germline and tumor‐testing. This approach often duplicates resources. The current prospective study assessed the feasibility of tumor‐first multigene testing by comparing tumor tissue with germline testing of peripheral blood using an 18‐gene NGS panel in 106 patients.
Elisabeth Spenard, Cristina Mitric, Melanie Care, Tracy L. Stockley, Raymond H. Kim, Jeanna McCuaig, Blaise Clarke, Laura Ranich, Clare Sheen, Sarah E. Ferguson, Liat Hogen, Taymaa May, Marcus Q. Bernardini   +12 more
wiley   +1 more source

European guidelines from the EHTG and ESCP for Lynch syndrome: an updated third edition of the Mallorca guidelines based on gene and gender

BJS (British Journal of Surgery), EarlyView., 2020
Recommendations for clinical and molecular identification of LS, surgical and endoscopic management of LS‐associated colorectal cancer and preventive measures for cancer were produced. The emphasis was on surgical and gastroenterological aspects of the cancer spectrum.
T. T. Seppälä, A. Latchford, I. Negoi, A. Sampaio Soares, R. Jimenez‐Rodriguez, L. Sánchez‐Guillén, D. G. Evans, N. Ryan, E. J. Crosbie, M. Dominguez‐Valentin, J. Burn, M. Kloor, M. von Knebel Doeberitz, F. J. B. van Duijnhoven, P. Quirke, J. R. Sampson, P. Møller, G. Möslein, on behalf of the European Hereditary Tumour Group (EHTG) and European Society of Coloproctology (ESCP)   +18 more
wiley   +1 more source